Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries. Bulk files are centralized on the Download page.
201-250 of 2,070
Spatial Domains
Dominant neighborhood compartment and purity from Tier 1 domain summaries.
2,069 ready
| Sample | Organ | Disease state | Cells | Dominant compartment ?Largest Tier 1 spatial domain by sample fraction; this is a biological neighborhood label, not a row-count summary. | Domain share | Purity | Diversity |
|---|---|---|---|---|---|---|---|
| NSCLC_38242124__IMC__175_B5,1 | Lung | Primary cancer | 5,849 | Tumor/Malignant | 59.9% | 0.99 | 0.07 |
| NSCLC_38242124__IMC__175_B5,10 | Lung | Primary cancer | 3,111 | Tumor/Malignant | 59.8% | 0.97 | 0.10 |
| NSCLC_38242124__IMC__175_B5,11 | Lung | Primary cancer | 3,572 | Tumor/Malignant | 74.6% | 0.99 | 0.03 |
| NSCLC_38242124__IMC__175_B5,12 | Lung | Primary cancer | 3,967 | Tumor/Malignant | 75.0% | 0.96 | 0.13 |
| NSCLC_38242124__IMC__175_B5,13 | Lung | Primary cancer | 2,364 | Stromal | 34.8% | 0.93 | 0.26 |
| NSCLC_38242124__IMC__175_B5,14 | Lung | Primary cancer | 3,391 | Tumor/Malignant | 79.4% | 0.98 | 0.08 |
| NSCLC_38242124__IMC__175_B5,15 | Lung | Primary cancer | 2,515 | Tumor/Malignant | 53.1% | 0.93 | 0.23 |
| NSCLC_38242124__IMC__175_B5,16 | Lung | Primary cancer | 2,891 | Tumor/Malignant | 41.0% | 0.75 | 0.57 |
| NSCLC_38242124__IMC__175_B5,17 | Lung | Primary cancer | 3,442 | Tumor/Malignant | 42.2% | 0.86 | 0.44 |
| NSCLC_38242124__IMC__175_B5,2 | Lung | Primary cancer | 3,313 | Other | 50.7% | 0.90 | 0.29 |
| NSCLC_38242124__IMC__175_B5,3 | Lung | Primary cancer | 3,516 | Tumor/Malignant | 82.0% | 0.98 | 0.07 |
| NSCLC_38242124__IMC__175_B5,4 | Lung | Primary cancer | 3,890 | Tumor/Malignant | 68.2% | 0.98 | 0.09 |
| NSCLC_38242124__IMC__175_B5,5 | Lung | Primary cancer | 3,985 | Tumor/Malignant | 40.6% | 0.94 | 0.21 |
| NSCLC_38242124__IMC__175_B5,6 | Lung | Primary cancer | 3,188 | Tumor/Malignant | 57.0% | 0.96 | 0.16 |
| NSCLC_38242124__IMC__175_B5,7 | Lung | Primary cancer | 3,997 | Tumor/Malignant | 54.5% | 0.95 | 0.18 |
| NSCLC_38242124__IMC__175_B5,8 | Lung | Primary cancer | 2,196 | Tumor/Malignant | 33.9% | 0.87 | 0.41 |
| NSCLC_38242124__IMC__175_B5,9 | Lung | Primary cancer | 3,264 | Tumor/Malignant | 75.1% | 0.97 | 0.10 |
| NSCLC_38242124__IMC__175_B6,1 | Lung | Primary cancer | 5,482 | Tumor/Malignant | 32.3% | 0.76 | 0.52 |
| NSCLC_38242124__IMC__175_B6,10 | Lung | Primary cancer | 3,587 | Tumor/Malignant | 58.7% | 0.97 | 0.11 |
| NSCLC_38242124__IMC__175_B6,11 | Lung | Primary cancer | 3,189 | Tumor/Malignant | 79.2% | 0.99 | 0.05 |
| NSCLC_38242124__IMC__175_B6,12 | Lung | Primary cancer | 3,515 | Tumor/Malignant | 91.4% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__175_B6,13 | Lung | Primary cancer | 1,900 | Stromal | 54.1% | 0.91 | 0.28 |
| NSCLC_38242124__IMC__175_B6,14 | Lung | Primary cancer | 3,094 | Tumor/Malignant | 42.2% | 0.98 | 0.08 |
| NSCLC_38242124__IMC__175_B6,15 | Lung | Primary cancer | 2,936 | Tumor/Malignant | 56.8% | 0.92 | 0.25 |
| NSCLC_38242124__IMC__175_B6,16 | Lung | Primary cancer | 2,433 | Tumor/Malignant | 56.0% | 0.90 | 0.30 |
| NSCLC_38242124__IMC__175_B6,17 | Lung | Primary cancer | 3,239 | Stromal | 49.5% | 0.54 | 0.62 |
| NSCLC_38242124__IMC__175_B6,2 | Lung | Primary cancer | 2,696 | Tumor/Malignant | 65.6% | 0.93 | 0.21 |
| NSCLC_38242124__IMC__175_B6,3 | Lung | Primary cancer | 3,549 | Tumor/Malignant | 66.7% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__175_B6,4 | Lung | Primary cancer | 1,915 | Tumor/Malignant | 53.5% | 0.96 | 0.18 |
| NSCLC_38242124__IMC__175_B6,5 | Lung | Primary cancer | 2,363 | Tumor/Malignant | 56.2% | 0.93 | 0.23 |
| NSCLC_38242124__IMC__175_B6,6 | Lung | Primary cancer | 2,579 | Tumor/Malignant | 58.6% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__175_B6,7 | Lung | Primary cancer | 3,749 | Tumor/Malignant | 50.7% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__175_B6,8 | Lung | Primary cancer | 2,866 | Stromal | 45.7% | 0.87 | 0.41 |
| NSCLC_38242124__IMC__175_B6,9 | Lung | Primary cancer | 5,561 | Tumor/Malignant | 86.0% | 0.97 | 0.08 |
| NSCLC_38242124__IMC__175_B7,1 | Lung | Primary cancer | 823 | Tumor/Malignant | 41.8% | 0.93 | 0.22 |
| NSCLC_38242124__IMC__175_B7,10 | Lung | Primary cancer | 3,104 | Stromal | 55.5% | 0.89 | 0.33 |
| NSCLC_38242124__IMC__175_B7,11 | Lung | Primary cancer | 3,417 | Immune | 33.0% | 0.33 | 0.97 |
| NSCLC_38242124__IMC__175_B7,12 | Lung | Primary cancer | 3,705 | Tumor/Malignant | 78.9% | 1.00 | 0.03 |
| NSCLC_38242124__IMC__175_B7,13 | Lung | Primary cancer | 3,302 | Tumor/Malignant | 27.2% | 0.73 | 0.57 |
| NSCLC_38242124__IMC__175_B7,14 | Lung | Primary cancer | 3,561 | Tumor/Malignant | 45.5% | 0.91 | 0.26 |
| NSCLC_38242124__IMC__175_B7,15 | Lung | Primary cancer | 5,889 | Immune | 63.1% | 0.99 | 0.05 |
| NSCLC_38242124__IMC__175_B7,16 | Lung | Primary cancer | 3,895 | Tumor/Malignant | 35.3% | 0.95 | 0.16 |
| NSCLC_38242124__IMC__175_B7,17 | Lung | Primary cancer | 2,340 | Tumor/Malignant | 45.5% | 0.93 | 0.25 |
| NSCLC_38242124__IMC__175_B7,2 | Lung | Primary cancer | 3,451 | Tumor/Malignant | 64.0% | 0.99 | 0.04 |
| NSCLC_38242124__IMC__175_B7,3 | Lung | Primary cancer | 2,129 | Tumor/Malignant | 47.0% | 0.88 | 0.36 |
| NSCLC_38242124__IMC__175_B7,4 | Lung | Primary cancer | 1,543 | Tumor/Malignant | 37.1% | 0.95 | 0.17 |
| NSCLC_38242124__IMC__175_B7,5 | Lung | Primary cancer | 2,916 | Tumor/Malignant | 62.5% | 0.99 | 0.07 |
| NSCLC_38242124__IMC__175_B7,6 | Lung | Primary cancer | 3,524 | Tumor/Malignant | 38.6% | 0.93 | 0.26 |
| NSCLC_38242124__IMC__175_B7,7 | Lung | Primary cancer | 3,227 | Tumor/Malignant | 31.5% | 0.94 | 0.27 |
| NSCLC_38242124__IMC__175_B7,8 | Lung | Primary cancer | 3,567 | Tumor/Malignant | 49.7% | 1.00 | 0.03 |